Abstract
A hallmark in most neurological disorders is a massive neuronal cell death, in which uncontrolled immune response is usually involved, leading to neurodegeneration. The vasoactive intestinal peptide (VIP) is a pleiotropic peptide that combines neuroprotective and immunomodulatory actions. Alterations on VIP/VIP receptors in patients with neurodenegerative diseases, together with its involvement in the development of embryonic nervous tissue, and findings found in VIP-deficient mutant mice, have showed the relevance of this endogenous peptide in normal physiology and in pathologic states of the central nervous system (CNS). In this review, we will summarize the role of VIP in normal CNS and in neurological disorders. The studies carried out with this peptide have demonstrated its therapeutic effect and render it as an attractive candidate to be considered in several neurological disorders linked to neuroinflammation or abnormal neural development.
Keywords: Neuroimmunology, neuroinflammatory diseases, neurological disorders, neuropeptides, VIP, TISSUE EXPRESSION, NORMAL ADULT BRAIN PHYSIOLOGY, neuroendocrine–immune communication, Neuroimmune interactions, multiple sclerosis (MS), Parkinson’s and Alzheimer´s disease (PD) and AD, NEURODEVELOPMENTAL DISORDERS.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:VIP in Neurological Diseases: More Than A Neuropeptide
Volume: 12 Issue: 4
Author(s): Maria Morell, Luciana Souza-Moreira and Elena Gonzalez-Rey
Affiliation:
Keywords: Neuroimmunology, neuroinflammatory diseases, neurological disorders, neuropeptides, VIP, TISSUE EXPRESSION, NORMAL ADULT BRAIN PHYSIOLOGY, neuroendocrine–immune communication, Neuroimmune interactions, multiple sclerosis (MS), Parkinson’s and Alzheimer´s disease (PD) and AD, NEURODEVELOPMENTAL DISORDERS.
Abstract: A hallmark in most neurological disorders is a massive neuronal cell death, in which uncontrolled immune response is usually involved, leading to neurodegeneration. The vasoactive intestinal peptide (VIP) is a pleiotropic peptide that combines neuroprotective and immunomodulatory actions. Alterations on VIP/VIP receptors in patients with neurodenegerative diseases, together with its involvement in the development of embryonic nervous tissue, and findings found in VIP-deficient mutant mice, have showed the relevance of this endogenous peptide in normal physiology and in pathologic states of the central nervous system (CNS). In this review, we will summarize the role of VIP in normal CNS and in neurological disorders. The studies carried out with this peptide have demonstrated its therapeutic effect and render it as an attractive candidate to be considered in several neurological disorders linked to neuroinflammation or abnormal neural development.
Export Options
About this article
Cite this article as:
Morell Maria, Souza-Moreira Luciana and Gonzalez-Rey Elena, VIP in Neurological Diseases: More Than A Neuropeptide, Endocrine, Metabolic & Immune Disorders - Drug Targets 2012; 12 (4) . https://dx.doi.org/10.2174/187153012803832549
DOI https://dx.doi.org/10.2174/187153012803832549 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PC12 Interaction with Magnetic Nanotubes: Effects on Viability, Cell Differentiation and Cell Translocation Induced by a Magnetic Field
Current Nanoscience The Role of Mitochondrial Function in Glutamate-Dependent Metabolism in Neuronal Cells
Current Pharmaceutical Design Epipolythiodioxopiperazines from Fungi: Chemistry and Bioactivities
Mini-Reviews in Medicinal Chemistry Role of the Insulin Receptor Variant Forms in Human Metabolic Disorders
Current Genomics Dynamic Expression of MicroRNAs (183, 135a, 125b, 128, 30c and 27a) in the Rat Pilocarpine Model and Temporal Lobe Epilepsy Patients
CNS & Neurological Disorders - Drug Targets Resisting the Sun with Vitamin D
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Ultrasound Assisted Synthesis of 2-alkynyl Pyrazolo[1,5-a]pyrimidines as Potential Anti-cancer Agents
Letters in Drug Design & Discovery Antiproliferative Effects of Molecular Iodine in Cancers
Current Chemical Biology Cell-Selective Mitochondrial Targeting: Progress in Mitochondrial Medicine
Current Drug Delivery Self-Assembled Micelles of Amphiphilic PEGylated Drugs for Cancer Treatment
Current Drug Targets Modulation of Tumour-Related Signaling Pathways by Natural Pentacyclic Triterpenoids and their Semisynthetic Derivatives
Current Medicinal Chemistry Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Other Anti- Inflammatory Agents in the Treatment of Neurodegenerative Disease
Current Alzheimer Research Evidence for the Role of Luteinizing Hormone in Alzheimer Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets HSV Amplicons: Neuro Applications
Current Gene Therapy Structural and Molecular Basis of Carbohydrate-Protein Interaction Systems as Potential Therapeutic Targets
Current Pharmaceutical Design Importance of Influx and Efflux Systems and Xenobiotic Metabolizing Enzymes in Intratumoral Disposition of Anticancer Agents
Current Cancer Drug Targets Crocetin: an Agent Derived from Saffron for Prevention and Therapy for Cancer
Current Pharmaceutical Biotechnology Biological Modulation by Lectins and Their Ligands in Tumor Progression and Metastasis
Anti-Cancer Agents in Medicinal Chemistry Antitumor Activities of Interleukin-27 on Melanoma
Endocrine, Metabolic & Immune Disorders - Drug Targets Nanoliposome is a Promising Carrier of Protein and Peptide Biomolecule for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry